National Institute Of Allergy And Infectious Diseases (niaid)

This early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…

This early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…

This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …

This early-stage trial tests a new booster vaccine called Boost-2867 in 140 healthy adults who have already been vaccinated against COVID-19. The vaccine is given either as a shot with or without adjuvants (ingredients that boost immune response) or as a nasal spray without adjuv…

This early-stage trial tests a new type of COVID-19 booster vaccine called PepGNP-COVID19. It uses tiny gold nanoparticles to train the immune system's T cells to recognize and fight the virus. The study involves 60 healthy adults aged 18-64 who will receive one of three doses to…

This study tests whether the HPV vaccine Gardasil 9 can trigger an immune response in people with idiopathic CD4 T cell lymphocytopenia (ICL), a rare condition that weakens the immune system. About 54 adults with ICL and some healthy volunteers will receive three doses of the vac…

This early-phase trial tests a new HIV vaccine strategy in 36 healthy adults without HIV. The vaccine uses ferritin nanoparticles to display HIV envelope proteins, followed by an mRNA boost. The goal is to safely trigger broadly neutralizing antibodies that could protect against …

This early-phase trial is testing two experimental HIV vaccines in 52 healthy adults without HIV. The goal is to see if the vaccines are safe and can stimulate the immune system to produce broadly neutralizing antibodies, which are key to fighting many HIV strains. Participants r…

This early-stage study tests an experimental HIV vaccine in 35 people living with HIV. The goal is to see if the vaccine can safely trigger the body to produce VRC01-class antibodies, which are known to neutralize many HIV strains. Participants will temporarily pause their antire…

This early-stage study tests two experimental mRNA vaccines designed to teach the body to make powerful antibodies that can neutralize many types of HIV. About 53 healthy adults without HIV will receive the vaccines to check safety and immune response. The goal is to see if the v…

This early-stage trial is testing two experimental HIV vaccines, DV700P-RNA and DV701B1.1-RNA, for the first time in people. The study will enroll 45 healthy adults without HIV to check if the vaccines are safe and whether they trigger an immune response. Participants will receiv…

This early-stage trial tests whether three experimental mRNA vaccines can safely teach the immune system to recognize and fight HIV. About 108 healthy, HIV-negative adults aged 18-55 will receive one of the vaccines. The main goal is to check for side effects and see if the vacci…

This early-stage trial tests two experimental HIV vaccines, UVAX-1107 and UVAX-1197, in 25 healthy adults without HIV. The goal is to check if the vaccines are safe and whether they trigger an immune response. Participants will receive injections and be followed for about a year.

This study compares three treatments for early HIV infection: zidovudine (AZT) alone, alpha-interferon alone, or both together. It aims to see which best lowers viral load, protects the immune system, and delays the first serious infection. About 180 adults with early HIV and hea…

This study tested whether monthly injections of two HIV drugs (cabotegravir and rilpivirine) work better than daily oral pills for people with HIV who have a history of missing doses. Over 450 participants were enrolled. The goal was to see if the long-acting shots reduce the cha…

This study tests a gene therapy for people with X-linked chronic granulomatous disease (X-CGD), a genetic condition that weakens the immune system and leads to severe infections. Researchers take the patient's own stem cells, add a working copy of the faulty gene, and return the …

This study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…

This study tests whether two lab-made antibodies, 3BNC117-LS and 10-1074-LS, can safely reduce the hidden HIV reservoir in people already on suppressive antiretroviral therapy (ART). The trial involves 105 adults with HIV who will receive three infusions of the antibodies or a pl…

This Phase 2 trial tests whether a combination of dasatinib and quercetin (D+Q) can safely improve physical function in 82 older adults with HIV who are frail or prefrail. Participants take D+Q or a placebo in six 2-day cycles over 12 weeks, then are monitored for another 12 week…

This study tests a new gene therapy for X-linked severe combined immunodeficiency (X-SCID), a rare immune disorder. Doctors take a person's own stem cells, fix a faulty gene using a technique called base editing, and return the cells to the body. The goal is to rebuild the immune…

This early-phase trial tests whether infusing specially grown donor-specific regulatory T cells (Tregs) can allow liver transplant recipients to safely reduce or stop their anti-rejection medications. Nine participants will receive a single dose of these cells and be monitored fo…

Some people waiting for a kidney transplant have immune systems that reject most donors, leading to years of waiting. This study tests whether two drugs—carfilzomib (used for multiple myeloma) and belatacept (an immune-suppressing drug)—can reduce that sensitivity. About 21 parti…

This study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…

This phase 1 trial tests a new therapeutic HIV vaccine (CH505 TF chTrimer) in 30 adults living with HIV who are on suppressive antiretroviral therapy. The vaccine is designed to stimulate the immune system to produce new antibodies against HIV. The study is currently suspended an…

This study tests a new gene therapy for people with chronic granulomatous disease (CGD), a genetic disorder that weakens the immune system and makes them prone to serious infections. The treatment takes the patient's own blood stem cells, adds a missing gene in the lab, and puts …

This study tests whether adding dupilumab (Dupixent) to standard asthma care can prevent asthma attacks in 240 urban children and teens aged 6–17 with severe, allergy-driven asthma. Participants receive either dupilumab or a placebo for 12 months. The main goal is to see if the d…

This study tests whether two drugs, daratumumab and belatacept, can lower the immune system's sensitivity in kidney transplant candidates who are very hard to match. About 19 highly sensitized patients will receive the treatment to see if it reduces their antibody levels or allow…

This study aimed to see if lower doses of chemotherapy drugs, with or without radiation, could safely prepare children and adults with SCID for a stem cell transplant. The goal was to help the donor cells take hold while avoiding severe side effects. However, the trial was withdr…

This Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth…

This study tests whether the meningitis vaccine Bexsero can also prevent gonorrhea, a common sexually transmitted infection. About 2,600 adults aged 18-50 who are at higher risk for gonorrhea will receive either the vaccine or a placebo. Researchers will track how many get infect…

This study looks at whether giving C-section babies a dose of their mother's vaginal bacteria can help prevent allergies and asthma. Researchers believe that babies born by C-section miss out on beneficial bacteria that help train the immune system. The study involves 114 infants…

This large phase 3 study tests whether a long-acting injectable drug called cabotegravir, given every 2 months, is safe and effective for preventing HIV in women. Over 3,200 HIV-negative women are taking part, comparing the shot to daily oral Truvada. The goal is to see if the in…

This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.

This study gives approved researchers access to stored blood samples and data from people who took part in earlier HIV studies. The goal is to learn more about HIV and help develop vaccines. All participants gave permission for their samples to be used in future research. Privacy…

This study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…

This study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…

This study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…

This study looks at HIV-infected adults who have been on antiretroviral therapy for a long time and have very low virus levels. Researchers want to see if the virus stays stable or changes over time. Participants visit the clinic every six months for blood tests and a special whi…

This study looks at people who have severe allergic reactions (anaphylaxis), especially when the cause is unknown. Researchers will do blood tests and bone marrow biopsies to find genetic or molecular clues. The goal is to understand what goes wrong in the body, not to test a new…

This study follows 583 adults who recovered from COVID-19 or were close contacts. Researchers will track their health, mental well-being, and immune responses over 3 years to understand long-term effects and whether prior infection prevents reinfection. Participants undergo regul…

This study looks at whether a combination of two anti-HIV antibodies can keep the virus under control after people stop their daily HIV medications. Researchers will compare people who received the antibodies in a previous study to those who got a placebo. Participants will pause…

This study enrolls 2500 pregnant women and follows their children from before birth up to age 3 (or 6 for those who continue). Researchers collect biosamples and environmental data to identify early-life markers and biological pathways that lead to food allergy and atopic dermati…

This study screens healthy volunteers aged 18-39 who self-report African ancestry for alpha globin deletions, which cause alpha thalassemia. Participants provide a one-time saliva sample by mail or in person. The goal is to learn how these genetic changes affect blood vessels, wh…

This study aims to understand how the immune system responds to a second infection with a mild bird flu virus (H10N7). Healthy adults who were infected with H10N7 in a previous study will be infected again and monitored closely in the hospital for 9 days. The goal is to learn mor…

This study follows 200 people who have had the flu to see how their immune system changes over two years. Participants give blood and nasal samples every three months. The goal is to learn how long antibodies last and how they change, which could help create more effective flu va…

This study was designed to see if giving a single dose of an antibody called L9LS changes how well the R21/Matrix-M malaria vaccine works. It planned to enroll healthy adults and infants in Mali. However, the trial was withdrawn before any participants were enrolled, so no data w…

This study tracks how often people of all ages in two Liberian villages get malaria, and how many mosquitoes carry the parasite. Researchers will test blood samples monthly and collect mosquitoes from homes. The goal is to gather data that could help decide the best way to use a …

This study looks at how having intestinal worms (helminths) and COVID-19 antibodies changes the immune system and gut bacteria. Researchers will collect blood and stool samples from 1500 people in India to measure infections and immune markers. The goal is to understand these int…

This study aimed to see if the BCG vaccine, given as a skin injection, could stop the TB bacteria from growing in healthy adults. Researchers planned to vaccinate some volunteers and then expose them to a weakened form of TB six months later to measure protection. However, the tr…